Objective: To investigate the association of insulin receptor substrate-2 (IRS-2) G1057D polymorphism with type 2 diabetes and obesity in Asian Indians. Methods: The study comprised of 1193 normal glucose tolerant (NGT) subjects and 1018 subjects with type 2 diabetes, aged X20 years with an average body mass index of 23.774.6 and 25.374.2 kg/m 2 , respectively. The subjects were unrelated and randomly selected from the Chennai Urban Rural Epidemiology Study (CURES), a population-based study in Chennai in southern India. The G1057D polymorphism of the IRS-2 gene was genotyped using PCR-RFLP assay. Results: The genotype frequency of the IRS-2 G1057D polymorphism was significantly different between the NGT and type 2 diabetic groups (P ¼ 0.0007) in the total study subjects and among the obese subjects (P ¼ 0.00007). Logistic regression analysis showed that the DD genotype showed an increased susceptibility to diabetes with an odds ratio (adjusted for age and sex) of 2.19 (95% CI: 1.34-3.57, P ¼ 0.002) when compared to the GG þ GD genotype, among the obese subjects, but not in non obese subjects. In order to explore possible interaction with obesity, logistic regression analysis was performed and the coefficient corresponding to the interaction parameter (genotype Â obesity) was significant (P ¼ 0.0001). Conclusion: In Asian Indians, the DD genotype increases susceptibility to type 2 diabetes by interacting with obesity.
Introduction
Insulin receptor substrate-2 (IRS-2), one of the major substrates of the insulin receptor, has a crucial role in insulin signalling 1 and in beta cell development and survival. 2, 3 While several polymorphisms have been identified in the IRS-2 gene, the association of the Gly1057Asp polymorphism (G1057D, rs1805097) with type 2 diabetes has been studied in Danish, 4 Finnish, Chinese, Swedish 5, 6 and German 7 populations, but the results have been inconsistent. A study from eastern Italy reported an association of this polymorphism with lower risk of diabetes in lean people, but with a higher risk in obese people suggesting that there could be a gene environment interaction. 8 A study in Pima Indians also suggested that the presence of obesity could influence the susceptibility of this polymorphism to diabetes. 9 The G1057D polymorphism has not been investigated in Asian Indians who have an increased susceptibility to diabetes, and currently have the largest number of diabetic subjects in the world. 10 Earlier studies both on migrant and native Asian Indians have shown high prevalence rates of the components of the metabolic syndrome namely hyperinsulinaemia, 11 insulin resistance 12 and diabetes. 13 It was shown by the senior author that plasma insulin levels, a surrogate marker of insulin resistance, were higher in Asian Indians compared to Europeans 11 and glucose clamp studies confirmed that Asian Indians have greater degree of insulin resistance. 12 Subsequently, several studies have confirmed these findings. 14, 15 Additionally, Asian Indians have been shown to have increased waist to hip ratio for any given body mass index (BMI) indicating increased prevalence of central body obesity. 16, 17 Further, for any given amount of adipose tissue, Asian Indians were shown to have lower insulin sensitivity. 18 All these studies suggest that there could be a genetic predisposition to obesity, insulin resistance and diabetes in Asian Indians. The objective of this study was to investigate whether the G1057D polymorphism was associated with diabetes in Asian Indians and whether there was any relationship between obesity and this gene polymorphism in conferring susceptibility to type 2 diabetes in this population.
Materials and methods

Subjects
A total of 2211 unrelated subjects were chosen from the Chennai Urban Rural Epidemiology Study (CURES). Chennai Urban Rural Epidemiology Study is an ongoing epidemiological study conducted on a representative population (aged X20 years) of Chennai (formerly Madras), the fourth largest city in India with a population of about 4.2 million. The methodology of the study has been discussed elsewhere 19 and the sampling frame is shown in our website www.mvdsc.org/mdrf/WORLD/pages/pages/chennai.html. Briefly, in Phase 1 of the urban component of CURES, 26 001 individuals were recruited based on a systematic random sampling technique. Self-reported diabetic subjects were classified as 'known diabetic subjects'. Fasting capillary blood glucose was determined using a One Touch Basic Glucometer (Life scan Johnson & Johnson, Milpitas, CA, USA) in all subjects. In Phase 2 of CURES, all known diabetic subjects (n ¼ 1529) were invited to our centre for a detailed study. In addition, in Phase 3 of CURES, every tenth individual of the 26 001 individuals screened in Phase 1 (n ¼ 2600) were invited to undergo oral glucose tolerance test (OGTT) using 75 g oral glucose load (dissolved in 250 ml of water). Those who were confirmed by OGTT to have 2 h plasma glucose value X11.1 mmol/l (based on WHO consulting group criteria) were labelled as 'newly detected diabetic subjects'. Subjects who were confirmed by OGTT to have fasting plasma glucose o5.6 mmol/l and 2 h plasma glucose value o7.8 mmol/l were categorised as normal glucose tolerance (NGT). 20 From the CURES study population, we randomly selected 1193 subjects with NGT and 1018 with type 2 diabetes. Of the known diabetic subjects, 8.2% were on diet only, 81.1% were on sulphonylureas and 9.7% were on insulin therapy for management of diabetes.
Measurement of clinical and biochemical variables
Anthropometric measurements including weight, height, waist and hip were obtained using standardised techniques. The BMI was calculated using the formula, weight (kg)/height (m
). The subjects chosen for the study were categorised according to their BMI as per the Asia Pacific Guidelines (non obese: BMI o25 kg/m 2 ; obese: BMIX25 kg/m 2 ). 21 Among the NGT subjects, 34% were obese and among the type 2 diabetic subjects 48% were obese. A fasting blood sample was taken and serum separated and stored at À701C until the assays were performed. Biochemical analyses were performed on Hitachi-912 Autoanalyser (Hitachi, Germany) using kits supplied by Roche Diagnostics (Mannheim, Germany). Fasting plasma glucose (GOD-POD method), serum cholesterol (CHOD-PAP method), serum triglycerides (GPO-PAP method) and HDL cholesterol (Direct method-polyethylene glycol-pretreated enzymes) were measured. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. 22 Glycated haemoglobin (HbA1C) was estimated by high-performance liquid chromatography using the Variant machine (Bio-Rad, Hercules, CA, USA). Serum insulin concentration was estimated using Dako kits (Dako, Glostrup, Denmark).
Isolation of DNA and genotype analysis DNA was isolated from whole blood using the PhenolChloroform method. The primers used were -forward 5 0 -AGC TCC CCC AAG TCT CCT AA-3 0 and reverse primer 5 0 -GGC CAC ACC AAA AGC CAT CT-3 0 (Alpha DNA). A final reaction volume of 25 ml of polymerase chain reaction (PCR) contained 100 ng genomic DNA, 5 pmol of each primer, PCR buffer with 1.5 mM of MgCl 2 , 100 mM of each dNTP, 10% dimethylsulphoxide and 0.5 U of Taq polymerase (Gibco, Invitrogen, NY, USA). Polymerase chain reaction was carried out on a Peltier Thermal Cycler (PTC-200, MJ Research Inc.) using the following conditions: 951C for 4 min, followed by 30 cycles of 951C for 30 s, 571C for 30 s, 721C for 30 s and a final extension of 721C for 5 min. The nucleotide substituition at codon 1057 was detected by digesting the 291 bp product with HhaI restriction enzyme. The resulting products 268 and 23 bp were electrophoresed on a 3% agarose gel. Based on the analysis of 400 blind duplicates (20%), there was 100% concordance in the genotyping. The genotyping success rate was B98%. Results Table 1 shows the clinical and biochemical characteristics of the NGT and diabetic subjects. The diabetic subjects were Table 2 shows the genotype and allele frequencies of the G1057D variant in the study subjects. The genotypic distribution in both the NGT and the type 2 diabetic group was in Hardy-Weinberg Equilibrium. There was no significant difference in the frequency of the 'D' allele between the NGT and diabetic subjects. Owing to the complex inheritance pattern of type 2 diabetes, different genetic models that could be compatible with the data were tested. The frequency of the GD genotype was lower and that of DD higher in type 2 diabetes subjects compared to those in the NGT group and the codominant, dominant and recessive models confirmed these significant differences in genotype frequency (P ¼ 0.0007, 0.040 and 0.020, respectively).
Statistical analysis
When the subjects were stratified based on obesity (Table 3) , again the frequency of GD genotype was lower and DD genotype higher in the obese type 2 diabetic group compared to obese NGT group under codominant (P ¼ 0.00007) and recessive (P ¼ 0.001) models. There were no differences in genotype frequency between NGT and type 2 diabetic subjects among the non obese group. The genotypic distribution in all the groups except the obese diabetic group was in Hardy-Weinberg Equilibrium.
On comparing the genotypes pairwise, we found that among the obese group, there was significant increase of risk of type 2 diabetes of DD over both GG (odds ratio (OR): 1.79, 95% confidence interval (CI): 1.08-2.98, P ¼ 0.024) and GD (OR: 2.75, 95% CI: 1.64-4.60, P ¼ 0.0001). When compared to GG, GD was significantly protective against diabetes (OR: 0.65, 95% CI: 0.48-0.86, P ¼ 0.003). The difference in the behaviour of obese subjects with GD and DD genotype, GD being protective against diabetes and DD being susceptible to the disease proved that the genotypic distribution of the obese study subjects was not compatible with a codominant model. Hence, codominant model was not analysed further.
When logistic regression was performed according to a recessive model (taking GG þ GD as reference), the DD genotype showed an increased susceptibility to diabetes with an OR (adjusted for age and sex) of 2.19 (95% CI: 1.34-3.57, P ¼ 0.002) in the obese subjects. In the non obese subjects, the DD genotype did not show any association with diabetes (Table 3) . To test for the interaction between the DD genotype and obesity, logistic regression analysis was performed using diabetes status as the dependent variable. The independent variables used were genotype (GG þ GD as 0 and DD as 1), obesity (BMI o25 kg/m 2 as 0, BMIX25 kg/m 2 as 1) and genotype Â obesity. The coefficient corresponding to the interaction parameter (genotype Â obesity) was significant (P ¼ 0.0001), the 95% CI for exponential of the parameter was (1.86, 6.45). A comparison of the clinical and biochemical characteristics of the NGT and diabetic group in relation to GG þ GD Vs DD genotypes did not show any significant differences in either of the groups (data not shown).
Discussion
The major finding of our study is that in Asian Indians, the D1057D genotype of IRS-2 is susceptible to diabetes by interacting with obesity. A Danish study first identified this frequent polymorphism but no association with type 2 diabetes was seen. 4 Subsequently, another study reported decreased serum insulin and C-peptide concentrations during an oral glucose tolerant test in middle-aged glucose tolerant Danish male subjects carrying the D1057 allele. 6 Earlier studies in Germans showed no association between this polymorphism and either insulin sensitivity or insulin secretory function, 7 whereas in the same population this polymorphism interacted with obesity to affect beta cell function. 23 Studies from
Italy and Japan failed to show an association between this polymorphism and type 2 diabetes. 24, 25 Thus, there appears to be marked difference in the association of the D1057 allele and diabetes, emphasising the need for studies in other populations. The molecular mechanism by which the nonconservative G1057D variant affects insulin action is not clear, but it is hypothesised that this introduces a charged amino acid (D) in place of a neutral one (G) in the domain of IRS-2 molecule located in between two putative tyrosine phosphorylation sites (at positions 1042 & 1072) of the protein which could produce alterations in downstream signalling through IRS-2. 8 Type 2 diabetes is polygenic and its development is due to the simultaneous inheritance of genetic variants at multiple loci interacting with several environmental factors, each having a small effect. Hence, an association between a given genetic polymorphism and diabetes might be missed when analysing only the overall prevalence of the polymorphism but it may be revealed when taking into account not only the confounders, but also the effect modifiers, such as obesity. Recent studies on knockout mice have shown that dysregulation of IRS-2 in beta cells and hypothalamus causes obesity, insulin resistance and diabetes. 26, 27 Although it is difficult to extrapolate these results to human beings, numerous studies have shown the allelic variants at the human IRS-2 gene to be linked to obesity, glucose intolerance and polycystic ovarian syndrome. 23, 28, 29 In the present study, the role of DD genotype in conferring susceptibility to type 2 diabetes became evident only in the presence of obesity. Our findings suggest that the DD genotype favours the development of diabetes in obese Asian Indians by interacting with obesity. Therefore, obesity seems to act as an effect modifier, increasing the risk of type 2 diabetes in DD homozygous individuals. Interaction of obesity with DD genotype has been reported in Pima Indians 9 and an Italian study 8 has shown this on all the carriers of D allele.
Confirmation of this in a relatively lean but high-risk Asian Indian population suggests that the IRS-2 gene confers susceptibility to diabetes in the presence of obesity. Since there may be some concern that the average age of NGT subjects is lower than that of subjects with type 2 diabetes, we performed an analysis with the control subjects restricted to those above 50 years of age. The results were similar to that obtained with all the control subjects. It was found that among the obese subjects, the DD genotype was susceptible to diabetes with an OR of 2.29 (95% CI: 1.02-5.15, P ¼ 0.044) when compared to the GG þ GD genotypes.
Additionally, we found some evidence of the protective role of GD in the presence of obesity towards developing type 2 diabetes. This may be consistent with the phenomenon of molecular heterosis, which refers to situations where a trait is significantly greater or lesser in individuals heterozygous at a specific gene marker than those homozygous for either allele. 30 However, we need to carry out further validation of this phenomenon as well as functional studies before we confirm the presence of heterosis. At the loci close to the true susceptibility locus, we do not expect either the cases or the controls to be in HardyWeinberg Equilibrium. This kind of departure is more pronounced in single gene disorders and less pronounced in complex disorders such as diabetes. The fact that the genotypic distribution of obese diabetic subjects at this polymorphism was not in Hardy-Weinberg Equilibrium strengthens the belief that G1057D polymorphism might be one of the putative loci for type 2 diabetes.
Two potential concerns of a study such as this could be its power and the problem of population stratification. A power calculation showed that the study had a power of 0.65 to detect the difference between the DD genotype and GG þ GD genotype.
It has been shown that there is significant diversity in allele frequencies at many autosomal loci within different castes in south India. 31 To address the issue of population stratification, we did a crossvalidation using genomic controls. 32 We performed a case-control study at five unlinked marker loci believed to be unrelated to diabetes but known to have allelic diversity among different populations. These loci were: Alu Repeat TPA-25 (subfamily: HS-2) on chromosome 8, Alu Repeat PV-92 (subfamily: HS-1) on chromosome 16, Alu Repeat FXIIIB (subfamily: HS-1) on chromosome 1, Alu Repeat ACE (subfamily: HS-1) on chromosome 17 and Alu Repeat D1 (subfamily: HS-1) on chromosome 3. The allele frequency difference between diabetic and NGT subjects was not statistically significant at any of the five loci studied. As we obtained a significant association of the G1057D polymorphism with diabetes in the presence of obesity, the genomic controls were analysed in this subset and we found no difference in the allele frequency between diabetic and NGT subjects. This indicates that the findings in this study are not likely to be an artefact of population substructuring.
In conclusion, the increased susceptibility of subjects with the DD genotype to diabetes owing to its interaction with obesity suggests that this genotype may serve as a genetic marker to identify the subset of Asian Indian obese individuals who are more susceptible to type 2 diabetes.
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